These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26689785)

  • 1. PCSK9 Inhibitors: A Technology Worth Paying For?
    Weintraub WS; Gidding SS
    Pharmacoeconomics; 2016 Mar; 34(3):217-20. PubMed ID: 26689785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
    Kazi DS; Penko J; Coxson PG; Moran AE; Ollendorf DA; Tice JA; Bibbins-Domingo K
    JAMA; 2017 Aug; 318(8):748-750. PubMed ID: 28829863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
    Tice JA; Kazi DS; Pearson SD
    JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572
    [No Abstract]   [Full Text] [Related]  

  • 4. Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases.
    Shah P
    Curr Cardiol Rep; 2018 May; 20(7):51. PubMed ID: 29779055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revisiting Outcomes-Based Pricing Propositions for the PCSK9 Inhibitor Evolocumab.
    Hernandez I
    JAMA Intern Med; 2017 Sep; 177(9):1388-1390. PubMed ID: 28783812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are PCSK9 Inhibitors Cost Effective?
    Korman MJ; Retterstøl K; Kristiansen IS; Wisløff T
    Pharmacoeconomics; 2018 Sep; 36(9):1031-1041. PubMed ID: 29777433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans.
    Kazi DS; Lu CY; Lin GA; DeJong C; Dudley RA; Chen R; Tseng CW
    JAMA Cardiol; 2017 Oct; 2(10):1164-1166. PubMed ID: 28903137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NICE recommends PCSK9 inhibitors for patients not responding to statins.
    Mayor S
    BMJ; 2016 May; 353():i2609. PubMed ID: 27159996
    [No Abstract]   [Full Text] [Related]  

  • 10. Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project.
    Hess PL; Kennedy K; Cowherd M; Virani SS; Masoudi FA; Navar AM; Yeh RW; Ho PM; Maddox TM
    Am Heart J; 2018 Jan; 195():151-152. PubMed ID: 29224643
    [No Abstract]   [Full Text] [Related]  

  • 11. Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums.
    Schulman KA; Balu S; Reed SD
    N Engl J Med; 2015 Oct; 373(17):1591-3. PubMed ID: 26444460
    [No Abstract]   [Full Text] [Related]  

  • 12. [PCSK9 inhibitors reduces LDL cholesterol by 60 percent].
    Nilsson P; Wiklund O
    Lakartidningen; 2017 Mar; 114():. PubMed ID: 28375534
    [No Abstract]   [Full Text] [Related]  

  • 13. CardioPulse: The European Medicines Agency's approval of proprotein convertase subtilisin/kexin type 9 inhibitors.
    Blind E; de Graeff PA; Meurs I; Holtkamp F; Baczynska A; Janssen H
    Eur Heart J; 2016 Feb; 37(6):502-3. PubMed ID: 26853264
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
    Henry CA; Lyon RA; Ling H
    Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk.
    Behr PEB; Moriguchi EH; Castro I; Bodanese LC; Dutra OP; Leães PE; Pimentel Filho P
    Arq Bras Cardiol; 2018 Jul; 111(1):104-108. PubMed ID: 30110052
    [No Abstract]   [Full Text] [Related]  

  • 16. Outcomes-Based Pricing as a Tool to Ensure Access to Novel but Expensive Biopharmaceuticals.
    Blumenthal DM; Goldman DP; Jena AB
    Ann Intern Med; 2017 Feb; 166(3):219-220. PubMed ID: 27951598
    [No Abstract]   [Full Text] [Related]  

  • 17. [Modern Lipid therapy today and tomorrow: anti-PCSK9 : A magic bullet concept following Paul Ehrlich].
    Erbel R; Gitt AK
    Herz; 2016 Jun; 41(4):271-2. PubMed ID: 27241696
    [No Abstract]   [Full Text] [Related]  

  • 18. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economics of PCSK-9 inhibitors.
    Schulman KA; Reed SD
    Am Heart J; 2017 Jul; 189():200-201. PubMed ID: 28625378
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness evaluation of the use of PCSK9 inhibitors.
    Civeira F; Pedro-Botet J
    Endocrinol Diabetes Nutr (Engl Ed); 2021; 68(6):369-371. PubMed ID: 34742469
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.